Interleukin-10 inhibition of the progression of established collagen-induced arthritis

Arthritis and Rheumatism

Volumn 39, Issue 3, 1996, Pages 495-503

  Walmsley, Marita ^a   Katsikis, Peter D ^a,b   Abney, Erika ^a   Parry, Sarah ^a   Williams, Richard O ^a   Maini, Ravinder N ^a   Feldmann, Marc ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN ANTIBODY; COLLAGEN TYPE 2; FREUND ADJUVANT; RECOMBINANT INTERLEUKIN 10; TUMOR NECROSIS FACTOR ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; IMMUNIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; SCORING SYSTEM;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CATTLE; COLLAGEN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG COMBINATIONS; INTERLEUKIN-10; MALE; MICE; MICE, INBRED DBA; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029959940     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780390318     Document Type: Article

References (48)

1. Mosmann TR: Properties and functions of interleukin-10. Adv Immunol 56:1-26, 1994
2. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR: Interleukin-10. Annu Rev Immunol 11:165-190, 1993
3. Florentine DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A: IL-10 inhibits cytokine production by activated macrophages. J Immunol 147:3815-3822, 1991
4. De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE: Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174:1209-1220, 1991
5. De Waal Malefyt R, Haanen J, Spits H, Roncarolo M-G, te Velde A, Figdor C, Johnson K, Kastelein R, Yssel H, de Vries JE: Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174:915-924, 1991
6. Gazzinelli RT, Oswald IP, James SL, Sher A: IL-10 inhibits parasite killing and nitric oxide production by IFN-γ activated macrophages. J Immunol 148:1792-1796, 1992
7. Cunha FQ, Moncada S, Liew FY: Interleukin-10 (IL-10) inhibits the induction of nitric oxide synthase by interferon-γ in murine macrophages. Biochem Biophys Res Commun 182:1155-1159, 1992
8. Mertz PM, DeWitt DL, Stetler-Stevenson WG, Wahl LM: Interleukin 10 supression of monocyte prostaglandin H synthase-2. Mechanism of inhibition of prostaglandin-dependent matrix metalloproteinase production. J Biol Chem 269:21322-21329, 1994
9. Ding L, Linsley P, Huang L-Y, Germain R, Shevach E: IL-10 inhibits macrophage co-stimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 151:1224-1234, 1993
10. Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G: Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes: evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med 178:2207-2211, 1993
11. Hsu DH, Moore KW, Spits H: Differential effects of IL-4 and IL-10 on IL-2 induced IFNγ synthesis and lymphokine-activated killer cell activity. Int Immunol 147:563-569, 1992
12. Rousset F, Garcia E, Deference T, Peronne C, Vezzio N, Hsu DH, Kastelein R, Moore KW, Banchereau J: IL-10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A 89:1890-1893, 1992
13. Thompson-Snipes L, Dhar V, Bond MW, Mosmann TR, Moore KW, Rennick DM: Interleukin 10: a novel stimulatory factor for mast cells and their progenitors. J Exp Med 173:507-510, 1991
14. O'Garra A, Chang R, Go N, Hastings R, Haughton G, Howard M: Ly-1 B (B-1) cells are the main source of B cell-derived interleukin-10. Eur J Immunol 22:711-717, 1992
15. Briere FD, Severt C, Bridon JM, Saint RJ, Banchereau J: Human interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3. J Exp Med 179:757-762, 1994
16. Te Velde AA, de Waal Malefyt R, Huijbens RJF, de Vries JE, Figdor CG: IL-10 stimulates monocyte FcgR surface expression and cytotoxic activity. Distinct regulation of antibody-dependent cellular cytotoxicity by IFN-γ, IL-4 and IL-10. J Immunol 149:4048-4052, 1992
17. Wogensen L, Huang X, Sarvetnick N: Leukocyte extravasation into the pancreatic tissue in transgenic mice expressing interleukin 10 in the Islets of Langerhans. J Exp Med 178:175-195, 1993
18. Wogensen L, Lee M-S, Sarvetnick N: Production of interleukin 10 by islet cells accelerates immune-mediated destruction of b cells in nonobese diabetic mice. J Exp Med 179:1379-1384, 1994
19. Jinquan T, Larsen CG, Gesser B, Matsushima K, Thestrup-Pederson K: Human IL- 10 is chemoattractant for CD8+ T lymphocytes and an inhibitor of IL-8-induced CD4+ T lymphocyte migration. J Immunol 151:4545-4551, 1993
20. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M: Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 179:305-310, 1994
21. Feldmann M, Brennan FM, Elliott M, Katsikis P, Maini RN: TNFa as a therapeutic target in rheumatoid arthritis. Circulatory Shock 43:179-184, 1994
22. Arend WP, Dayer J-M: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor a in rheumatoid arthritis. Arthritis Rheum 38:151-160, 1995
23. Chu CQ, Field M, Feldmann M, Maini RN: Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 34:1125-1132, 1991
24. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M: Inhibitory effect of TNFa antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2:244-247, 1989
25. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M: Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α. Eur J Immunol 21:2575-2579, 1991
26. Butler D, Scallon BJ, Meager T, Kissonerghis M, Corcoran A, Chernajovsky Y, Feldmann M, Ghrayeb J, Brennan FM: Comparison of soluble TNF-R-IgG fusion proteins, soluble monomeric p55-TNF-R and anti-TNF MAbs as inhibitors of TNF cytotoxicity in a human cell. Cytokine 6:616-623, 1994
27. Feldmann M, Brennan FM, Chantry D, Haworth C, Turner M, Abney E, Buchan G, Barrett K, Barkley D, Chu A, Field M, Maini RN: Cytokine production in the rheumatoid joint: implications for treatment. Ann Rheum Dis 49:480-486, 1990
28. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA: Involvement of endogenous tumour necrosis factor a and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A 89:7375-7379, 1992
29. Williams RO, Feldmann M, Maini RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Nat Acad Sci U S A 89:9784-9788, 1992
30. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a. Arthritis Rheum 36:1681-1690, 1993
31. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN: Randomised double blind comparison of a chimaeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110, 1994
32. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN: Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 344:1125-1127, 1994
33. Rankin ECC, Choy EHS, Kassimos D, Kingsley GH, Sopwith SM, Isenberg DA, Panayi GS: The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CD571) in rheumatoid arthritis. Br J Rheumatol 34:334-342, 1995
34. Feldmann M, Brennan FM, Walmsley M, Cohen S, Katsikis P, Maini RN: Homeostatic regulatory mechanisms in rheumatoid arthritis synovium: interleukin-10 is the major anti-inflammatory cytokine (abstract). In, Horizons in Medicine: Proceedings of the Advanced Medicine Conference, London, UK, February 13-16, 1995. London, Royal College of Physicians (in press)
35. Llorente L, Richaud-Patin Y, Fior R, Alcocer-Varela J, Wijdenes J, Fourrier BM, Galanaud P, Emilie D: In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus: a potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum 37:1647-1655, 1994
36. Cush JJ, Splawski JB, Thomas R, McFarlin JE, Schulze-Koops H, Davis LS, Fujita K, Lipsky PE: Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum 38:96-104, 1995
37. Katsikis P, Chu CQ, Brennan FM, Maini RN, Feldmann M: Immunoregulatory role of interleukin 10 (IL-10) in rheumatoid arthritis. J Exp Med 179:1517-1527, 1994
38. Staines NA, Wooley PH: Collagen-induced arthritis: what can it teach us? Br J Rheumatol 33:798-807, 1994
39. Dune FH, Fava RA, Noelle RJ: Collagen-induced arthritis as a model of rheumatoid arthritis. Clin Immunol Immunopathol 73:11-18, 1994
40. Sheehan KCF, Ruddle NH, Schreiber RD: Generation and characterization of hamster monoclonal antibodies that neutralize tumor necrosis factors. J Immunol 142:3884-3893, 1989
41. Liblau RS, Singer SM, McDevitt HO: Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 16:34-38, 1995
42. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W: Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77:510-514, 1992
43. Van Den Berg WB, Joosten LAB, Helsen M, Van De Loo FAJ: Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 95:237-243, 1994
44. Gerard C, Bruyns C, Marchant A, Abramowicz D, Vandenabeele P, Delvaux A, Fiers W, Goldman M, Velu T: Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 177:547-550, 1993
45. Howard M, Muchamuel T, Andrade S, Menon S: Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 177:1205-1208, 1993
46. Rott O, Fleischer B, Cash E: Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol 24: 1434-1440, 1994
47. Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, Padula SJ, Clark RB: An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 172:1193-1200, 1990
48. Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, Feldmann M: Control of established experimental allergic encephalomyelitis by inhibition of tumour necrosis factor activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 24: 2040-2048, 1994